Luba Greenwood reframes competition in biotech as a positive force. When multiple companies pursue the same biological target, it validates the target's importance and accelerates discovery. This collaborative mindset benefits the entire field and, ultimately, patients, as the best and safest drug will prevail.

Contrary to the focus on large upfront payments, a smarter partnership strategy is to negotiate for a larger share of downstream success through royalties and milestones. This can yield far greater long-term returns if the product succeeds.

Venture investors aren't concerned when a portfolio company launches products that compete with their other investments. This is viewed as a positive signal of a massive winner—a company so dominant it expands into adjacent categories, which is the ultimate goal.

In explosive markets like GLP-1 drugs, significant price drops and margin compression (e.g., from 80% to 60%) don't necessarily harm profits. The sheer volume of new customers can completely offset lower per-unit profitability, leading to far greater overall earnings.

For diseases like Idiopathic Pulmonary Fibrosis (IPF), existing treatments have such severe side effects that over half of patients refuse them. MannKind's strategy with its inhaled Nintendanib is based on the insight that physicians will prioritize a drug that patients can actually tolerate, even if it offers slightly less efficacy.

Latigo Bio sees the market entry of competitor Vertex's Nav1.8 drug not as a threat, but as a crucial step in market creation. Vertex's launch educates physicians and patients about a completely new class of pain medicine for the first time in decades, creating awareness and demand that a follower company like Latigo can then capitalize on with a potentially 'best-in-class' product.

Following its largest-ever acquisition, MannKind's CEO is deliberately pausing further M&A activity. Instead of being "always opportunistic," the company is prioritizing integration and successful launches to avoid distractions. This disciplined focus on execution is intended to build shareholder confidence before considering future acquisitions.

The acquisition of SC Pharma was driven less by the product itself and more by a strategic imperative to shift from a royalty-dependent model to one where MannKind controls the majority of its revenue. This gives them direct influence over their growth trajectory and aligns with shareholder desire for self-determination.

The CEO argues that a second entrant in a new drug class can expand the total market, citing historical examples. The goal isn't just to take share from the incumbent (BMS) but to increase diagnosis rates and physician adoption for the entire category, creating a "one plus one equals three" scenario.